- Conditions
- Retinitis Pigmentosa, Retinal Dystrophy
- Interventions
- Observational
- Other
- Lead sponsor
- Nanoscope Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Miami, Florida + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1417–1440
of 8,148
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Brain Tumors, Central Nervous System Tumors
- Interventions
- filgrastim, topotecan hydrochloride, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more
- Conditions
- Alzheimer's Disease
- Interventions
- ABT-089, placebo
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 337 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 42
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Fresno, California + 38 more
- Conditions
- Cervical Cancer
- Interventions
- tisotumab vedotin, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 502 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 53
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 28 more
- Conditions
- Breast Neoplasms
- Interventions
- Imlunestrant, Goserelin, Tamoxifen 20 mg
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 27 more
- Conditions
- Heart Failure, Iron-deficiency
- Interventions
- IV Iron Infusion Group
- Drug
- Lead sponsor
- Radha Gopalan
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Bronchiectasis
- Interventions
- BI 1291583, Placebo matching BI 1291583
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,755 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 78
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
- Conditions
- Brain Aneurysm
- Interventions
- Pipeline Embolization Device
- Device
- Lead sponsor
- Medtronic Neurovascular Clinical Affairs
- Industry
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 20 more
- Conditions
- Multiple Myeloma
- Interventions
- JNJ-79635322, Teclistamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 42
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 32 more
- Conditions
- Low Back Pain
- Interventions
- Tanezumab 20 mg IV, Placebo for naproxen, Tanezumab 10 mg IV, Tanezumab 5 mg IV, Placebo for tanezumab, Naproxen
- Biological · Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,359 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 135
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Hueytown, Alabama + 101 more
- Conditions
- Cardiac Surgery Requiring Cardiopulmonary Bypass and Median Sternotomy, Cardiopulmonary Bypass, Sternotomy
- Interventions
- Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D), TISSEEL VH fibrin sealant
- Drug
- Lead sponsor
- Baxter Healthcare Corporation
- Industry
- Eligibility
- 18 Years and older
- Timeline
- 2002 – 2004
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Orange, California • Gainesville, Florida + 19 more
- Conditions
- Arthroplasty
- Interventions
- Tapentadol IR (CG5503), Placebo, Oxycodone HCL IR
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 367 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 42 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Accu-Chek® CONNECT DMS, DMS
- Device
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 7 Years to 18 Years
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 10 more
- Conditions
- Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Capecitabine, Computed Tomography, Dose-escalated Radiation Therapy, Fluorouracil, Gemcitabine, Irinotecan Hydrochloride, Irinotecan Sucrosofate, Leucovorin Calcium, Magnetic Resonance Imaging, Nab-paclitaxel, Observation Activity, Oxaliplatin, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy, Tumor Treating Fields Therapy
- Procedure · Drug · Radiation + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 356 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 332
- States / cities
- Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 252 more
- Conditions
- Metastatic Ewing Sarcoma
- Interventions
- Vincristine, Doxorubicin, Cyclophosphamide, Ifosfamide, Actinomycin, Irinotecan, Cabozantinib, Topotecan, Temozolomide, Etoposide, Liposomal doxorubicin
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Hartford, Connecticut + 17 more
- Conditions
- Severe Tricuspid Regurgitation
- Interventions
- Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System, Edwards EVOQUE Tricuspid Valve Replacement (TTVR) System
- Device
- Lead sponsor
- Medtronic Cardiovascular
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2041
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Thousand Oaks, California + 9 more
- Conditions
- Atopic Dermatitis, Atopic, Dermatitis, AD, Eczema
- Interventions
- ATI-045, Placebo
- Drug
- Lead sponsor
- Aclaris Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 53
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Bryant, Arkansas + 47 more
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Obesity
- Interventions
- Metabolic surgery, Incretin-Based Therapy
- Procedure · Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Indianapolis, Indiana • Rochester, Minnesota + 1 more
- Conditions
- Cystic Fibrosis
- Interventions
- azithromycin 250 mg tablets, placebo tablets
- Drug
- Lead sponsor
- CF Therapeutics Development Network Coordinating Center
- Network
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Hartford, Connecticut • Atlanta, Georgia + 27 more
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
- Interventions
- Inhaled Treprostinil
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 243 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 91
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 67 more
- Conditions
- Hypothyroidism
- Interventions
- Isovue
- Drug
- Lead sponsor
- Bracco Diagnostics, Inc
- Industry
- Eligibility
- Up to 3 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Omaha, Nebraska • Akron, Ohio + 1 more
- Conditions
- COVID-19, Chronic Liver Disease
- Interventions
- Prospective Chart Review
- Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,025 participants
- Timeline
- 2020 – 2021
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Fresno, California + 15 more
- Conditions
- ALS
- Interventions
- MT-1186, Placebo
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 384 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Rogers, Arkansas + 30 more
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- Navlimetostat, Gemcitabine, Nab-paclitaxel, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 48
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Springdale, Arkansas + 38 more